RAMP 301 Aims to Solidify Avutometinib Plus Defactinib in Recurrent LGSOC
As investigators continue efforts to improve outcomes for patients with low-grade serous ovarian cancer, they are expanding investigations beyond chemotherapy.
Dr Salani on Research With MEK Inhibition in KRAS-Mutant Serous Ovarian Cancer
Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
Dr Brown on Ongoing Trials Targeting the RAS/MAPK Pathway in Ovarian Cancer
Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.
Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Dr Thaker on the RAMP-301 Trial of Avutometinib/Defactinib in Low-Grade Serous Ovarian Cancer
Premal Thaker, MD, MS, discusses the phase 3 RAMP-301 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
